In this study, a number of barriers associated with slowing cancer trial activation at an NCI-designated cancer center were identified.
View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.
SISAQOL Consortium presented their recommendations for the design and analysis of PRO data in randomized, controlled trials.
Researchers found that nutrition status and activity levels have a more significant influence on outcomes for participants in phase 1 and 2 clinical trials of cancer drugs than previously believed.
Compliance with Food and Drug Administration Amendments Act of 2007 low, not improving.